kfm 19 has been researched along with 1,3-dipropyl-8-cyclopentylxanthine in 5 studies
| Studies (kfm 19) | Trials (kfm 19) | Recent Studies (post-2010) (kfm 19) | Studies (1,3-dipropyl-8-cyclopentylxanthine) | Trials (1,3-dipropyl-8-cyclopentylxanthine) | Recent Studies (post-2010) (1,3-dipropyl-8-cyclopentylxanthine) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 1,301 | 1 | 165 |
| Protein | Taxonomy | kfm 19 (IC50) | 1,3-dipropyl-8-cyclopentylxanthine (IC50) |
|---|---|---|---|
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | 0.0051 | |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | 0.0038 | |
| Adenosine receptor A2a | Homo sapiens (human) | 0.2033 | |
| Adenosine receptor A2b | Homo sapiens (human) | 0.0234 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ichikawa, S; Ishii, A; Nonaka, H; Ono, E; Shimada, J; Shiozaki, S; Suzuki, F | 1 |
| Jacobson, KA; van Galen, PJ; Williams, M | 1 |
| Fuse, E; Ichikawa, S; Ishii, A; Kobayashi, H; Nakamura, J; Nonaka, H; Shimada, J; Shiozaki, S; Suzuki, F | 1 |
| Bondavalli, F; Botta, M; Bruno, O; Ciacci, A; Corelli, F; Fossa, P; Lucacchini, A; Manetti, F; Martini, C; Menozzi, G; Mosti, L; Ranise, A; Schenone, S; Tafi, A; Trincavellic, ML | 1 |
| Beckmann, H; Berger, W; Deckert, J; Heckers, S; Heinsen, H; Kleopa, K; Ransmayr, G; Riederer, P | 1 |
1 review(s) available for kfm 19 and 1,3-dipropyl-8-cyclopentylxanthine
| Article | Year |
|---|---|
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
Topics: Adenosine; Animals; Humans; Models, Chemical; Receptors, Purinergic; Second Messenger Systems; Structure-Activity Relationship | 1992 |
4 other study(ies) available for kfm 19 and 1,3-dipropyl-8-cyclopentylxanthine
| Article | Year |
|---|---|
7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: a potent and water-soluble adenosine A1 antagonist.
Topics: Adamantane; Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Guinea Pigs; Hemodynamics; Imidazoles; Purinergic Antagonists; Purinones; Rats; Receptors, Purinergic; Solubility; Vasodilator Agents | 1992 |
Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance.
Topics: Adenosine; Amnesia; Animals; Avoidance Learning; Diuretics; Male; Mice; Motor Activity; Phenylisopropyladenosine; Rats; Rats, Wistar; Receptors, Purinergic; Scopolamine; Structure-Activity Relationship; Xanthines | 1993 |
Synthesis, molecular modeling studies, and pharmacological activity of selective A(1) receptor antagonists.
Topics: Animals; Binding, Competitive; Cattle; Cerebral Cortex; Ligands; Models, Molecular; Purinergic P1 Receptor Antagonists; Pyridines; Radioligand Assay; Receptors, Purinergic P1; Structure-Activity Relationship | 2002 |
Adenosine A1 receptors in human hippocampus: inhibition of [3H]8-cyclopentyl-1,3-dipropylxanthine binding by antagonist drugs.
Topics: Aged; Anticonvulsants; Autoradiography; Binding, Competitive; Caffeine; Carbamazepine; Female; Hippocampus; Humans; Male; Middle Aged; Oxcarbazepine; Purinergic Antagonists; Receptors, Purinergic; Xanthines | 1993 |